Keyphrases
Precision Medicine
91%
GLP-1 Receptor Agonist
80%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
80%
Diabetes
75%
Type 2 Diabetes Mellitus (T2DM)
65%
Clinical Features
61%
Type 2 Diabetes Prevention
40%
Heterogeneous Treatment Effects
40%
Clinical Translation
40%
Second International
40%
Glucagon-like
40%
Inhibitor-1
40%
Drug Treatment
40%
Targeted Treatment
40%
International Consensus
40%
Consensus Document
40%
A1 Receptor
40%
Precision Diabetes
40%
Drug Response
40%
Receptor Agonist
40%
Glycemic Response
26%
Glycemic Outcomes
20%
Clinical Genomics
20%
Prescription Drugs
20%
Clinical Markers
20%
Type 2 Diabetic Patients
20%
Potential Treatments
20%
Randomized Trial
20%
Disease Progression
20%
Clinical Manifestations
20%
Glycemic Targets
20%
Genomic Markers
20%
Genomic Features
20%
Adverse Outcomes
20%
Genetic Markers
20%
Adverse Effects
20%
Molecular Genetics
20%
Individual-based
20%
Recent Advances
20%
Clinical Trials
20%
Predictive Marker
20%
Real-world Trials
20%
Molecular Features
20%
Clinical Implementation
20%
Specific Group
20%
Trial Data
20%
Tailored Treatment
20%
Disease Heterogeneity
20%
Average Effect
20%
Agonist Treatment
16%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Diabetes
84%
Personalized Medicine
83%
Sodium Glucose Cotransporter 2 Inhibitor
80%
Glycemic
63%
Treatment Effect
48%
Receptor
40%
Systematic Review
40%
Medicine
40%
Drug Therapy
40%
Targeted Therapy
40%
Glucagon-Like Peptide-1 Agonist
40%
Drug Response
40%
Clinical Feature
28%
Clinical Trial
28%
Cotransporter
22%
Body Mass Index
20%
Predictive Marker
20%
Disease Exacerbation
20%
Adverse Outcome
20%
Patient with Type 2 Diabetes
20%
Genetic Marker
20%
Adverse Effect
20%
Diseases
20%
Observational Study
11%
Cardiovascular System
11%
Randomized Controlled Trial
11%
Meta-Analysis
11%
Liraglutide
8%
Microvascular Complication
8%
Evidence-Based Medicine
5%
Kidney Function
5%
Post-Hoc Analysis
5%
Cost-Effectiveness Analysis
5%
Combination Therapy
5%
Insulin Release
5%
Medical Decision Making
5%
